ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

RESTYLANE REFYNE
Aesthetic medicine
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

RESTYLANE REFYNE PP

Generic Name and Formulations:
Hyaluronic acid 20mg/mL, lidocaine 3mg/mL; injectable gel implant.

Company:
Galderma Laboratories, Inc.

Therapeutic Use:

Indications for RESTYLANE REFYNE:

Correction of moderate-to-severe facial wrinkles and folds (eg, nasolabial folds).

Adult:

See full labeling. Inject slowly into the mid-to-deep dermis with least amount of pressure necessary. May use supplementary anesthesia during and post-inj. >21yrs: Individualize. Initial treatment: usually 1.5mL per site; repeat treatment: usually 1mL per site. May require touch-up treatments to achieve desired effects.

Children:

Not established.

Contraindications:

History of anaphylaxis or presence of multiple severe allergies. Allergies to Gram (+) bacterial proteins.

Warnings/Precautions:

Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to initiation. Avoid intravascular inj; discontinue immediately if changes in vision, signs of stroke, blanching of skin or unusual pain during or shortly after procedure occurs. Avoid sites with permanent implant. Risk of infection. Defer if active inflammatory process, infection or tumor is present at specific sites. Use in non-facial areas: not established. Possible risk of an inflammatory reaction at implant site if laser treatment, chemical peeling, or any other procedure based on active dermal response is considered after Restylane Refyne or if product is given before skin has healed completely after such a procedure. Bleeding disorders. Risk of herpes reactivation in patients with a history of herpetic eruption. Advise patients to avoid strenuous exercise and extensive sun or heat exposure within first 24hrs. Patients (<22yrs), pregnancy, nursing mothers: not established.

Interactions:

Caution with concomitant immunosuppressants. Increased bruising or bleeding at inj sites with concomitant aspirin, NSAIDs, warfarin.

Pharmacological Class:

Hyaluronan.

Adverse Reactions:

Inj site reactions (eg, redness, swelling, bruising, lump/bump formation, pain/tenderness, itching).

Generic Availability:

NO

How Supplied:

Single-use syringe—1 (w. needles)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs